Loading stock data…
STAA
$29.87-0.09 (-0.30%)
After Hours$29.87+0.00 (+0.00%)· Last close Jun 9
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
STAAR Surgical Company in the Healthcare sector is trading at $29.87. Wall Street consensus targets $29.67 (9 analysts), implying a -0.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $35.87, remaining 22.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$29.87
Potential Downside
0%
Whystock Fair Value$29.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$29.67-0.7%
Range$23.00 – $40.00
Fundamentals
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.97%
Volume
Today's trading volume
581,110
Recent News
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
How The STAAR Surgical (STAA) Story Is Shifting After Q1 And New Analyst Targets
STAAR Surgical’s modeled fair value has been updated from US$21.11 to US$29.67, a shift that puts a brighter spotlight on how analysts are recalibrating their expectations. That change sits alongside a mix of more optimistic and cautious views, with some firms lifting targets after a stronger Q1 and others still focused on patchy visibility, especially around China and future guidance. Read on to see what is driving the evolving narrative and how you can track it over time. Stay updated as...
Hedge Fund Broadwood Capital Added Over 1 Million Shares of STAAR Surgical to Its Position. Here's What That Means for Investors.
STAAR Surgical supplies implantable lenses for vision correction, serving ophthalmic surgeons and clinics globally with proprietary tech.
This Hedge Fund Just Dumped Its Entire Stake in XPeng Stock. Should You Too?
Look beyond the headlines. XPeng recently earned its first-ever profit and is aggressively expanding its global presence.
5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call
STAAR Surgical’s first quarter performance was met with a strong positive market reaction, reflecting the company’s progress in resolving prior operational disruptions and inventory challenges. Management credited this turnaround to robust sales in China, early momentum from the EVO+ lens launch, and a return to normalized distributor inventory levels. Interim Co-CEO Warren Foust emphasized, “We have now largely moved past many of the challenges that we faced in 2025...those issues are behind us